InvestmentAug 7, 2026, 04:43 PM
Silexion Therapeutics Files S-1 for Public Offering of Shares & Warrants
AI Summary
Silexion Therapeutics Corp filed an S-1 registration statement for a public offering of ordinary shares, pre-funded warrants, and ordinary warrants. H.C. Wainwright will serve as the exclusive placement agent, receiving various fees and warrants. The offering has no minimum requirement, which could impact the total proceeds. The company recently regained compliance with Nasdaq listing standards but remains under a monitoring period. Additionally, Silexion initiated a Phase 2/3 clinical trial for its lead product candidate, SIL204, in July 2026.
Key Highlights
- Proposed public offering of ordinary shares, pre-funded warrants, and ordinary warrants.
- H.C. Wainwright engaged as exclusive placement agent for the offering.
- Placement agent fees include 7.0% cash, 1.0% management, and 7.0% warrants.
- No minimum offering amount required, potentially reducing proceeds.
- Regained Nasdaq compliance; under monitoring until September 23, 2026.
- May 2026 warrant exercise generated $1.0 million in gross proceeds.
- Initiated Phase 2/3 clinical trial for SIL204 in pancreatic cancer in July 2026.
Price Impact
More from SLXN